Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q2 2025 · 10-Q
Revenue$11.49M$11.49M−88.0% vs Q2 2024 Net Income-$38.27M-$38.27MN/M vs Q2 2024 EPS Diluted-$0.17-$0.17N/M vs Q2 2024 Operating Income-$38,765,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$47,114,000N/M Margins · derivedOperating margin-337.4%−391.8 pt vs Q2 2024
Net margin-333.1%−384.5 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 5, 2025 · 36 d after period end